REDV is a synthetic peptide sequence (Arg-Glu-Asp-Val) that functions as a selective ligand for the integrin α4β1 receptor, which is highly expressed on the surface of endothelial cells. By mimicking the cell-binding domain of fibronectin, REDV promotes preferential endothelial cell adhesion and proliferation while reducing platelet adhesion and fibrinogen adsorption—quantified studies report a reduction in platelet deposition to near-zero levels on REDV-modified surfaces. Research applications include surface functionalization of vascular grafts, stents, and decellularized organ scaffolds to enhance endothelialization, as well as the design of targeted gene delivery nanoparticles that have demonstrated a rise in ZNF580 protein expression from 15.7% to 34.8%.